BioSpace News Archive

Genetown

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs

Zenas BioPharma announced the closing of an upsized $200 million Series C preferred stock financing.

May 7, 2024
·
6 min read
Business

Entrada Therapeutics Reports First Quarter 2024 Financial Results

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.

May 7, 2024
·
9 min read
Business

Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals, Inc. reports first-quarter 2024 financial results and provides corporate updates.

May 7, 2024
·
15 min read
Business

Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress

Zentalis® Pharmaceuticals, Inc. announced financial results for the quarter ended March 31, 2024, and highlighted recent corporate accomplishments.

May 7, 2024
·
11 min read
Business

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, reported its financial results for the first quarter ended March 31, 2024 and provided an update on recent clinical development pipeline and other corporate developments.

May 7, 2024
·
11 min read
Business

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Neumora Therapeutics, Inc. announced financial results for the first quarter ended March 31, 2024, and provided a business update.

May 7, 2024
·
9 min read
Business

Harvard Bioscience Announces First Quarter 2024 Financial ResultsStrong gross margin performance and focus on efficiency to support ongoing investments in growth

Harvard Bioscience, Inc. announced financial results for the first quarter ended March 31, 2024.

May 7, 2024
·
10 min read
Biotech Bay

Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference

Nurix Therapeutics, Inc. announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference at 9:30-9:55 a.m. ET, on Tuesday, May 14, 2024.

May 7, 2024
·
1 min read
Bio NC

BioCryst to Present at Upcoming May 2024 Investor Conferences

BioCryst Pharmaceuticals, Inc. announced that the company will present at the following conferences.

May 7, 2024
·
1 min read
Business

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results

Theriva™ Biologics reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

May 7, 2024
·
13 min read